Milatuzumab, previously known as MEDI-MEDI-115 Compound, represents a unique therapeutic targeting human leukemia-lymphoma marker 1 (hLL1), also identifiable by the identifier 899796-83-9. This antibody shows https://hannawpiv547700.blognody.com/profile